Status:
COMPLETED
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia
Lead Sponsor:
Thomas Jefferson University
Conditions:
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Phase Chronic Myelogenous Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This trial studies the feasibility and acceptability of a mobile intervention called txt4TKI for the improvement of tyrosine kinase inhibitor management in patients with chronic myeloid leukemia. Tyro...
Eligibility Criteria
Inclusion
- PHASE 1: Patients diagnosed with chronic myeloid leukemia
- PHASE 1: Initiated tyrosine kinase inhibitors therapy for a year
- PHASE 1: Able to read and understand English
- PHASE 1: Able to provide informed consent
- PHASE 1: Have a mobile phone with TXT capability
- PHASE 1: Know how to use TXT
- PHASE 2: Patients diagnosed with chronic myeloid leukemia in the chronic phase
- PHASE 2: Starting tyrosine kinase inhibitors therapy or has been on tyrosine kinase inhibitors with anticipation of at least 6 month duration of use
- PHASE 2: Able to read and understand English
- PHASE 2: Able to provide informed consent
- PHASE 2: Have a mobile device with TXT capability
- PHASE 2: Willing to use a wireless pill bottle during study for 6 months
- PHASE 2: Know or willing to learn how to use TXT
Exclusion
- • Cognitive impaired document in the electronic medical record (EMR)
Key Trial Info
Start Date :
June 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 8 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04694820
Start Date
June 5 2020
End Date
April 8 2022
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107